^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Estrogen receptor agonist

    Related drugs:
    3d
    CoCo3 - Comprehensive Health Effects of Combined Contraceptives: a 12-month randomized, controlled, open-label trial comparing E4+DRSP, EE 20?g+DRSP and DRSP-only (2025-523359-71-00)
    P4, N=156, Not yet recruiting, Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu
    New P4 trial
    6d
    PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, University of Pennsylvania | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    7d
    HNF1595-21: Estrogen replacement therapy (ERT) for treatment of adolescent anorexiannervosa An open label study (2024-519908-27-01)
    P1/2, N=36, Completed, Universitetssykehuset Nord-Norge HF | Not yet recruiting --> Completed
    Trial completion
    8d
    Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV (clinicaltrials.gov)
    P4, N=62, Not yet recruiting, Albert Einstein College of Medicine
    New P4 trial
    9d
    GONACLO: Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups (clinicaltrials.gov)
    P4, N=500, Enrolling by invitation, Szeged University
    New P4 trial
    9d
    Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (clinicaltrials.gov)
    P1, N=24, Completed, Atea Pharmaceuticals, Inc. | Not yet recruiting --> Completed
    Trial completion
    13d
    Melanoma Cells Exposed to Clomiphene Citrate Respond With Cell Cycle Arrest and Reduced Invasiveness. (PubMed, J Appl Toxicol)
    Gene expression analysis revealed decreased N-cadherin/CDH2 (p < 0.05) and SOD2 (p < 0.01) gene expression in the presence of CC, suggesting antimetastatic and prooxidant effects. These results indicate that direct exposure to CC does not promote aggressive melanoma cell behavior in vitro.
    Journal
    |
    CDH2 (Cadherin 2) • SOD2 (Superoxide Dismutase 2)
    1m
    Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial (clinicaltrials.gov)
    P2, N=58, Recruiting, University of Utah | Trial completion date: Apr 2027 --> Jan 2029 | Trial primary completion date: Dec 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    1m
    An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (clinicaltrials.gov)
    P1, N=24, Completed, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting --> Completed
    Trial completion
    1m
    Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, University of Washington
    New P2 trial • HEOR
    |
    AR (Androgen receptor)
    |
    Divigel (estradiol)
    2ms
    VITAL-E: Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Stratpharma AG | Trial completion date: Nov 2025 --> Sep 2026 | Trial primary completion date: Nov 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • Head-to-Head
    2ms
    EstraMemo: Estradiol and Intrusive Memories (clinicaltrials.gov)
    P=N/A, N=273, Recruiting, Charite University, Berlin, Germany
    New trial
    |
    estradiol valerate